Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board
Amsterdam, the Netherlands and London, UK – 1 May 2024 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, tod
Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
The Next Generation Synthetic Lethality Precision Oncology Company The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large
Tessellate BIO Emerges from Stealth
The Next Generation Synthetic Lethality Precision Oncology Company The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large